Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05959109 | A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants | PHASE1 | COMPLETED | 57 | — | — | Jul 21, 2023 | Jan 11, 2024 | Jan 29, 2024 | 1 | United States |
PK: Cmax of Peresolimab
PK: AUC\[0-tlast\] of Peresolimab
PK: AUC(0-∞) of Peresolimab
| Arm | Type | Description |
|---|---|---|
| Peresolimab (Test 1) | EXPERIMENTAL | Peresolimab administered subcutaneously (SC). |
| Peresolimab (Test 2) | EXPERIMENTAL | Peresolimab administered SC. |
| Peresolimab (Test 3) | EXPERIMENTAL | Peresolimab administered SC. |
| Peresolimab (Reference) | EXPERIMENTAL | Peresolimab administered SC. |
| Name | Type | Description |
|---|---|---|
| Peresolimab | DRUG | Administered SC |
Inclusion Criteria: * Male and female participants who are overtly healthy as determined by medical history, physical examination, and other screening procedures * A minimum body weight of 45 kilograms and body mass index (BMI) between 18.0 and 32.0 kilograms per meter squared (kg/m²), inclusive, a...